Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
Coalition of Blood for Africa (CoBA) has shared a post on LinkedIn:
“Blood shortages
30-day expiry limits
Type matching chaos
Japan may have just solved all three.
At Nara Medical University, researchers are engineering a breakthrough in transfusion medicine — artificial blood that:
Doesn’t require blood type matching
Lasts up to 2 years (vs. 30 days for regular donations)
Is… purple
How?
Professor Hiromi Sakai and her team have developed a synthetic blood substitute by extracting hemoglobin from expired blood donations and encapsulating it in a virus-proof shell.
No blood type compatibility issues
Converts medical waste into lifesaving supply
Ideal for trauma, surgery, and remote care
Clinical trials are already underway, with human participants receiving 100–400ml doses. If successful, Japan aims for nationwide use by 2030.
Meanwhile, Professor Teruyuki Komatsu at Chuo University is developing artificial oxygen carriers using albumin (a plasma protein) — targeting use in stroke treatment, haemorrhage, and acute pressure crashes.
Why this matters
Global blood supply is often fragile — especially during disasters, pandemics, and in low-resource settings.
Artificial blood could extend shelf life 24x longer than current donations.
Eliminating type-matching delays could revolutionize emergency care.
This is not just scientific progress, it could be the most significant advance in transfusion medicine in decades, with massive implications for maternal health, surgery, battlefield medicine, and disaster response.
The future of blood may not be red.
It may be purple — and always ready when we need it most.”
Discover more on Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin